A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

<b>Objective</b>: Rat sarcoma (Ras) proteins, Kirsten, Harvey, and Neuroblastoma rat sarcoma viral oncogene homolog (KRAS, HRAS, and NRAS, respectively), are a family of GTPases, which are key regulators of cellular growth, differentiation, and apoptosis through signal transduction pathways modulated by growth factors that have been recognized to be dysregulated in PCOS. This study explores Ras signaling proteins and growth factor-related proteins in polycystic ovary syndrome (PCOS). <b>Methods</b>: In a well-validated PCOS database of 147 PCOS and 97 control women, plasma was batch analyzed using Somascan proteomic analysis for circulating KRas, Ras GTPase-activating protein-1 (RASA1), and 45 growth factor-related proteins. The cohort was subsequently stratified for BMI (body mass index), testosterone, and insulin resistance (HOMA-IR) for subset analysis. <b>Results</b>: Circulating KRas, and RASA1 did not differ between PCOS and control women (<i>p</i> > 0.05). EGF1, EGFR, and EGFRvIII were decreased in PCOS (<i>p</i> = 0.04, <i>p</i> = 0.04 and <i>p</i> < 0.001, respectively). FGF8, FGF9, and FGF17 were increased in PCOS (<i>p</i> = 0.02, <i>p</i> = 0.03 and <i>p</i> = 0.04, respectively), and FGFR1 was decreased in PCOS (<i>p</i> < 0.001). VEGF-D (<i>p</i> < 0.001), IGF1 (<i>p</i> < 0.001), IGF-1sR (<i>p</i> = 0.02), and PDGFRA (<i>p</i> < 0.001) were decreased in PCOS compared to controls. After stratifying for BMI ≤ 29.9 kg/m<sup>2</sup>, EGFR FGF8, FGFR1 VEGF-D, IGF1, and IGF-1sR differed (<i>p</i> < 0.05) though EGF1, EGFRvIII, FGF8, FGFR1, and VEGF-D no longer differed; after subsequently stratifying for HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed between groups (<i>p</i> < 0.05). <b>Conclusions</b>: Several growth factors that activate Ras differ between women with and without PCOS, and when stratified for BMI and HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed; these appear to be inherent features of the pathophysiology of PCOS.

Authors

Institutions

Publication Details

Journal
Cells
Published
2025-03-05
DOI
https://doi.org/10.3390/cells14050377
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

Akiko Takemoto, Alexandra E. Butler, Sara Anjum Niinuma, Thozhukat Sathyapalan et al.
Cells
Ovarian function and disorders
article

A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

Akiko Takemoto, Alexandra E. Butler, Sara Anjum Niinuma, Thozhukat Sathyapalan, Stephen L. Atkin, Priya Das, Haniya Habib
article en

Abstract

<b>Objective</b>: Rat sarcoma (Ras) proteins, Kirsten, Harvey, and Neuroblastoma rat sarcoma viral oncogene homolog (KRAS, HRAS, and NRAS, respectively), are a family of GTPases, which are key regulators of cellular growth, differentiation, and apoptosis through signal transduction pathways modulated by growth factors that have been recognized to be dysregulated in PCOS. This study explores Ras signaling proteins and growth factor-related proteins in polycystic ovary syndrome (PCOS). <b>Methods</b>: In a well-validated PCOS database of 147 PCOS and 97 control women, plasma was batch analyzed using Somascan proteomic analysis for circulating KRas, Ras GTPase-activating protein-1 (RASA1), and 45 growth factor-related proteins. The cohort was subsequently stratified for BMI (body mass index), testosterone, and insulin resistance (HOMA-IR) for subset analysis. <b>Results</b>: Circulating KRas, and RASA1 did not differ between PCOS and control women (<i>p</i> > 0.05). EGF1, EGFR, and EGFRvIII were decreased in PCOS (<i>p</i> = 0.04, <i>p</i> = 0.04 and <i>p</i> < 0.001, respectively). FGF8, FGF9, and FGF17 were increased in PCOS (<i>p</i> = 0.02, <i>p</i> = 0.03 and <i>p</i> = 0.04, respectively), and FGFR1 was decreased in PCOS (<i>p</i> < 0.001). VEGF-D (<i>p</i> < 0.001), IGF1 (<i>p</i> < 0.001), IGF-1sR (<i>p</i> = 0.02), and PDGFRA (<i>p</i> < 0.001) were decreased in PCOS compared to controls. After stratifying for BMI ≤ 29.9 kg/m<sup>2</sup>, EGFR FGF8, FGFR1 VEGF-D, IGF1, and IGF-1sR differed (<i>p</i> < 0.05) though EGF1, EGFRvIII, FGF8, FGFR1, and VEGF-D no longer differed; after subsequently stratifying for HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed between groups (<i>p</i> < 0.05). <b>Conclusions</b>: Several growth factors that activate Ras differ between women with and without PCOS, and when stratified for BMI and HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed; these appear to be inherent features of the pathophysiology of PCOS.

CellsVol. 14(5)
Royal College of Surgeons in Ireland - Bahrain (BH), Hull York Medical School (GB)
Openalex Percentile: Top 93%
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.